For nonalcoholic fatty liver disease, which drug is conditionally recommended?

• A. Methotrexate
• B. Leflunomide
• C. Hydroxychloroquine
• D. TNF inhibitors

Answer: (A)

When managing nonalcoholic fatty liver disease, the focus is on limiting liver injury while treating any accompanying conditions. Drugs that can harm the liver require careful consideration; they are not routinely used in NAFLD, and any use is typically conditional, with close monitoring and a favorable risk-benefit balance.

Methotrexate stands out as a conditionally considered option because it is known to have hepatotoxic potential, so it isn’t used freely. In a patient who also needs disease-modifying therapy for another condition, methotrexate can be chosen only if the benefits justify the liver risk, with stringent monitoring of liver enzymes and other safety measures. The other agents listed carry higher risks for the liver or lack clear evidence supporting their use in NAFLD, making them less appropriate as conditional choices in this context.